Monday 24 August 2015, Amsterdam
The report, now available on ASDReports, “European Injectable Drug Delivery Market by Type (Device, Formulation), Therapeutic (Hormonal, Oncology), Usage Pattern (Curative Care, Immunization), Administration (Skin, Musculoskeletal), End User (Hospital, Home care Setting) - Forecast to 2020”, provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the European injectable drug delivery market along with estimates and forecasts of the revenue and market share analysis.
The European Injectable Drug Delivery market is expected to reach $207.3 Billion by 2020 from $114.7 Billion in 2015, growing at a CAGR of 12.6% from 2015 to 2020. Injectable drug delivery offers a promising alternative for the delivery of drugs that are ineffective when administered orally. Injectable drug delivery is aimed to maximize patient compliance and reduce the frequency of dosage administration without compromising the effectiveness of the treatment.
The report segments the European injectable drug delivery market on the basis of types, therapeutic applications, usage patterns, modes of administration, end users, and regions. On the basis of type, the formulations segment is expected to account for the largest share in 2015, closely followed by the devices segment. The formulations segment is expected to grow at the highest CAGR during the forecast period, owing to the rising prevalence of chronic diseases, increase in demand of self-injection devices, growth of the biologics market, technological advancements, emphasis on innovation of formulations, and benefits such high efficacy and reduced side effects offered by formulations. The formulations market is further segmented into conventional drug delivery formulations, novel drug delivery formulations, and long-acting injection formulations. The devices market is further segmented into conventional injection devices, self-injections, and other devices.
On the basis of therapeutic application, the European injectable drug delivery market is segmented into autoimmune diseases, hormonal disorders, oncology, orphan diseases, and other therapeutic applications. On the basis of usage pattern, the market is segmented into curative care, immunization, and others.
On the basis of mode of administration, the European injectable drug delivery market is segmented into skin, organs, central nervous system, and circulatory/musculoskeletal system. On the basis of end user, the market is segmented into hospitals/clinics, home care settings, research laboratories, pharma and biotech companies, and other end users.
Geographically, the market is dominated by Germany, followed by France. Germany is expected to account for the largest share of the European injectable drug delivery market in 2015, with the highest growth rate during the forecast period.
Key players in the European injectable drug delivery market include Becton, Dickinson and Company (U.S.), Baxter International Inc. (U.S.), Gerresheimer AG (Germany), Pfizer Inc. (U.S.), Schott AG (Germany), Sandoz,(Germany) Teva Pharmaceutical Industries Ltd. (Israel), and Eli Lilly and Company (U.S.).
ASDReports.com Media contact: S. Koopman -
Marketing and Communications
ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : email@example.com
back to News